Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.

The WATCHMAN FLX device showed superior safety with 8.5% major bleeding at 36 months, compared to 18.1% with oral ...

11月16日，西安医学院第一附属医院心血管内科二病区、介入诊疗科团队成功完成了医院首例房颤Pulsed FA脉冲电场消融联合WATCHMAN ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...

Boston Scientific (NYSE:BSX) stock climbed 5% Monday after the medical device maker announced a study has shown its Watchman ...

Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...

近日，西安交通大学第二附属医院心血管病院王洪涛副主任心脏电生理团队，成功完成西北地区首例一站式FARAPULSE脉冲导管消融联合Watchman ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC ...